China Traditional Chinese Medicine Holdings Co. Limited (0570.HK)
HKD 2.31
(-0.86%)
HKD 2.31
(-0.86%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 18.12 Billion CNY | 26.69% |
| 2022 | 14.3 Billion CNY | -24.92% |
| 2021 | 19.05 Billion CNY | 28.68% |
| 2020 | 14.8 Billion CNY | 3.39% |
| 2019 | 14.32 Billion CNY | 27.2% |
| 2018 | 11.25 Billion CNY | 35.03% |
| 2017 | 8.33 Billion CNY | 27.63% |
| 2016 | 6.53 Billion CNY | 76.12% |
| 2015 | 3.7 Billion CNY | 37.89% |
| 2014 | 2.69 Billion CNY | 92.9% |
| 2013 | 1.39 Billion CNY | 36.58% |
| 2012 | 1.02 Billion CNY | 24.19% |
| 2011 | 822.22 Million CNY | 2.73% |
| 2010 | 800.39 Million CNY | 35.65% |
| 2009 | 590.05 Million CNY | 51.09% |
| 2008 | 390.53 Million CNY | 17.14% |
| 2007 | 333.38 Million CNY | 203.29% |
| 2006 | 109.92 Million CNY | -87.19% |
| 2005 | 857.77 Million CNY | 8.69% |
| 2004 | 789.16 Million CNY | 3.3% |
| 2003 | 763.93 Million CNY | -1.72% |
| 2002 | 777.28 Million CNY | -7.21% |
| 2001 | 837.68 Million CNY | -1.62% |
| 2000 | 851.49 Million CNY | 0.97% |
| 1999 | 843.28 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 4.19 Billion CNY | -4.91% |
| 2024 Q2 | 4.19 Billion CNY | 0.0% |
| 2023 Q1 | 4.65 Billion CNY | 10.85% |
| 2023 Q3 | 4.4 Billion CNY | -5.2% |
| 2023 FY | 18.12 Billion CNY | 26.69% |
| 2023 Q4 | 4.4 Billion CNY | 0.0% |
| 2023 Q2 | 4.65 Billion CNY | 0.0% |
| 2022 Q2 | 2.95 Billion CNY | 0.0% |
| 2022 Q1 | 2.95 Billion CNY | -45.78% |
| 2022 FY | 14.3 Billion CNY | -24.92% |
| 2022 Q4 | 4.19 Billion CNY | 0.0% |
| 2022 Q3 | 4.19 Billion CNY | 41.97% |
| 2021 Q3 | 5.45 Billion CNY | 33.8% |
| 2021 Q4 | 5.45 Billion CNY | 0.0% |
| 2021 FY | 19.05 Billion CNY | 28.68% |
| 2021 Q1 | 4.07 Billion CNY | -0.02% |
| 2021 Q2 | 4.07 Billion CNY | 0.0% |
| 2020 FY | 14.8 Billion CNY | 3.39% |
| 2020 Q3 | 4.07 Billion CNY | 22.47% |
| 2020 Q2 | 3.32 Billion CNY | 0.0% |
| 2020 Q4 | 4.07 Billion CNY | 0.0% |
| 2020 Q1 | 3.32 Billion CNY | -9.87% |
| 2019 Q4 | 3.69 Billion CNY | 0.0% |
| 2019 Q2 | 3.46 Billion CNY | 0.0% |
| 2019 Q1 | 3.46 Billion CNY | 19.65% |
| 2019 FY | 14.32 Billion CNY | 27.2% |
| 2019 Q3 | 3.69 Billion CNY | 6.44% |
| 2018 Q4 | 2.89 Billion CNY | 0.0% |
| 2018 FY | 11.25 Billion CNY | 35.03% |
| 2018 Q3 | 2.89 Billion CNY | 6.15% |
| 2018 Q2 | 2.73 Billion CNY | 0.0% |
| 2018 Q1 | 2.73 Billion CNY | 23.04% |
| 2017 FY | 8.33 Billion CNY | 27.63% |
| 2017 Q4 | 2.21 Billion CNY | 0.0% |
| 2017 Q1 | 1.94 Billion CNY | 16.97% |
| 2017 Q3 | 2.21 Billion CNY | 13.84% |
| 2017 Q2 | 1.94 Billion CNY | 0.0% |
| 2016 Q1 | 1.59 Billion CNY | 39.87% |
| 2016 FY | 6.53 Billion CNY | 76.12% |
| 2016 Q4 | 1.66 Billion CNY | 0.0% |
| 2016 Q3 | 1.66 Billion CNY | 4.2% |
| 2016 Q2 | 1.59 Billion CNY | 0.0% |
| 2015 Q4 | 1.14 Billion CNY | 0.0% |
| 2015 Q1 | 711.03 Million CNY | 0.81% |
| 2015 FY | 3.7 Billion CNY | 37.89% |
| 2015 Q2 | 711.03 Million CNY | 0.0% |
| 2015 Q3 | 1.14 Billion CNY | 60.85% |
| 2014 Q4 | 705.34 Million CNY | 0.0% |
| 2014 FY | 2.69 Billion CNY | 92.9% |
| 2014 Q3 | 705.34 Million CNY | 13.79% |
| 2014 Q2 | 619.87 Million CNY | 0.0% |
| 2014 Q1 | 619.87 Million CNY | 41.27% |
| 2013 Q2 | 258.51 Million CNY | 0.0% |
| 2013 Q4 | 438.79 Million CNY | 0.0% |
| 2013 Q3 | 438.79 Million CNY | 69.74% |
| 2013 FY | 1.39 Billion CNY | 36.58% |
| 2013 Q1 | 258.51 Million CNY | -7.28% |
| 2012 Q1 | 255.27 Million CNY | 0.0% |
| 2012 Q2 | 255.27 Million CNY | 0.0% |
| 2012 Q3 | 276.85 Million CNY | 8.45% |
| 2012 Q4 | 278.81 Million CNY | 0.71% |
| 2012 FY | 1.02 Billion CNY | 24.19% |
| 2011 Q1 | 205.55 Million CNY | 0.0% |
| 2011 FY | 822.22 Million CNY | 2.73% |
| 2011 Q4 | 255.27 Million CNY | 24.19% |
| 2011 Q3 | 205.55 Million CNY | 0.0% |
| 2011 Q2 | 205.55 Million CNY | 0.0% |
| 2010 Q4 | 205.55 Million CNY | 2.73% |
| 2010 FY | 800.39 Million CNY | 35.65% |
| 2010 Q3 | 200.09 Million CNY | 0.0% |
| 2010 Q1 | 200.09 Million CNY | 0.0% |
| 2010 Q2 | 200.09 Million CNY | 0.0% |
| 2009 Q3 | 147.51 Million CNY | 0.0% |
| 2009 Q1 | 147.51 Million CNY | 0.0% |
| 2009 Q2 | 147.51 Million CNY | 0.0% |
| 2009 Q4 | 200.09 Million CNY | 35.65% |
| 2009 FY | 590.05 Million CNY | 51.09% |
| 2008 Q1 | 97.63 Million CNY | 0.0% |
| 2008 FY | 390.53 Million CNY | 17.14% |
| 2008 Q4 | 147.51 Million CNY | 51.09% |
| 2008 Q3 | 97.63 Million CNY | 0.0% |
| 2008 Q2 | 97.63 Million CNY | 0.0% |
| 2007 Q3 | 83.34 Million CNY | 0.0% |
| 2007 Q4 | 97.63 Million CNY | 17.14% |
| 2007 FY | 333.38 Million CNY | 203.29% |
| 2007 Q1 | 83.34 Million CNY | 0.0% |
| 2007 Q2 | 83.34 Million CNY | 0.0% |
| 2006 Q1 | 27.48 Million CNY | 0.0% |
| 2006 FY | 109.92 Million CNY | -87.19% |
| 2006 Q4 | 83.34 Million CNY | 203.29% |
| 2006 Q3 | 27.48 Million CNY | 0.0% |
| 2006 Q2 | 27.48 Million CNY | 0.0% |
| 2005 Q2 | 214.44 Million CNY | 0.0% |
| 2005 Q4 | 27.48 Million CNY | -87.19% |
| 2005 Q3 | 214.44 Million CNY | 0.0% |
| 2005 Q1 | 214.44 Million CNY | 0.0% |
| 2005 FY | 857.77 Million CNY | 8.69% |
| 2004 Q2 | 197.29 Million CNY | 0.0% |
| 2004 Q3 | 197.29 Million CNY | 0.0% |
| 2004 Q4 | 214.44 Million CNY | 8.69% |
| 2004 FY | 789.16 Million CNY | 3.3% |
| 2004 Q1 | 197.29 Million CNY | 0.0% |
| 2003 Q1 | 190.98 Million CNY | 0.0% |
| 2003 FY | 763.93 Million CNY | -1.72% |
| 2003 Q4 | 197.29 Million CNY | 3.3% |
| 2003 Q2 | 190.98 Million CNY | 0.0% |
| 2003 Q3 | 190.98 Million CNY | 0.0% |
| 2002 Q2 | 194.32 Million CNY | 0.0% |
| 2002 Q3 | 194.32 Million CNY | 0.0% |
| 2002 FY | 777.28 Million CNY | -7.21% |
| 2002 Q4 | 190.98 Million CNY | -1.72% |
| 2002 Q1 | 194.32 Million CNY | 0.0% |
| 2001 Q2 | 209.42 Million CNY | 0.0% |
| 2001 Q1 | 209.42 Million CNY | 0.0% |
| 2001 FY | 837.68 Million CNY | -1.62% |
| 2001 Q4 | 194.32 Million CNY | -7.21% |
| 2001 Q3 | 209.42 Million CNY | 0.0% |
| 2000 Q2 | 212.87 Million CNY | 0.0% |
| 2000 Q1 | 212.87 Million CNY | 0.0% |
| 2000 FY | 851.49 Million CNY | 0.97% |
| 2000 Q4 | 209.42 Million CNY | -1.62% |
| 2000 Q3 | 212.87 Million CNY | 0.0% |
| 1999 Q2 | 210.82 Million CNY | 0.0% |
| 1999 Q3 | 210.82 Million CNY | 0.0% |
| 1999 Q4 | 212.87 Million CNY | 0.97% |
| 1999 FY | 843.28 Million CNY | 0.0% |
| 1999 Q1 | 210.82 Million CNY | 0.0% |
| 1998 Q4 | 210.82 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -6892.592% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | -72.104% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -30564.085% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -2211.813% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -1785.159% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -1620.919% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | -961.897% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -2139.736% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -4354.089% |
| SSY Group Limited | 6.46 Billion HKD | -180.394% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -2694.794% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | -1134.629% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 93.298% |